Palonosetron

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

43 API Suppliers, 21 USDMF, 3 JDMF, 8 EU WC, 4 KDMF, 12 NDC API, 23 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

31 Drugs in Development

31 Drugs in Development

INTERMEDIATES

13 Intermediate Suppliers

13 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

96 FDF Dossiers, 34 FDA Orange Book, 24 Europe, 2 Canada, 4 Australia, 9 South Africa, 23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE, SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML), POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL, SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML), INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 2 Rochem International Inc, 16 SPI Pharma, 7 DKSH, 3 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 Pfanstiehl, 4 Kirsch Pharma, 4 ACG Worldwide, 6 Actylis, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 1 CD Formulation, 3 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures, 2 Ingredion Pharma Solutions, 2 Kerry, 2 Keval Exports, 3 Lonza Capsugel, 9 Microlex e.U, 3 Nitika Pharmaceutical Specialities, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 1 Qualicaps, 22 Roquette, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 3 Silverline Chemicals, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

48 Fillers, Diluents & Binders, 18 Disintegrants & Superdisintegrants, 18 Direct Compression, 17 Thickeners and Stabilizers, 17 Lubricants & Glidants, 16 Taste Masking, 16 Chewable & Orodispersible Aids, 16 Parenteral, 11 Film Formers & Plasticizers, 11 Co-Processed Excipients, 10 Granulation, 9 Coating Systems & Additives, 8 Empty Capsules, 5 Controlled & Modified Release, 3 Solubilizers, 3 Emulsifying Agents, 2 API Stability Enhancers, 2 Coloring Agents, 2 Topical, 2 Rheology Modifiers, 1 Soft Gelatin

DIGITAL CONTENT

64 News #PharmaBuzz

64 News #PharmaBuzz

GLOBAL SALES INFORMATION

17 US Medicaid Prescriptions, 10 Regulatory FDF Prices, 10 Annual Reports

MARKET PLACE

9 APIs, 6 FDF Dossiers

PATENTS & EXCLUSIVITIES

36 US Patents, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

9 Others

9 Others

$ Xls

Filters

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Akynzeo Beats Standard Care in Preventing Chemo Nausea

17 Oct 2025

// GLOBENEWSWIRE

Helsinn Group submits new Akynzeo formulation to EMA

02 Apr 2025

// GLOBENEWSWIRE

Avenacy Launches Palonosetron Hydrochloride Injection In US Market

22 Jul 2024

// BUSINESSWIRE

Helsinn Group launches Akynzeo injection in US market

26 Jun 2024

// PHARMABIZ

Helsinn & Chugai sign a partnership agreement renewal to commercialize AKYNZEO

12 Jun 2024

// GLOBENEWSWIRE

Nanjing King's Generic Palonosetron Hydrochloride Receives Approval in the U.S.

14 Aug 2023

// FDA

Palonosetron

Palonosetron

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

43 API Suppliers

21 USDMF

3 JDMF

8 EU WC

4 KDMF

12 NDC API

23 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

31 Drugs in Development

INTERMEDIATES

13 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

96 FDF Dossiers

34 FDA Orange Book

24 Europe

2 Canada

4 Australia

9 South Africa

23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE

SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL

SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)

INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Minakem

2 Rochem International Inc

16 SPI Pharma

7 DKSH

3 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

1 Pfanstiehl

4 Kirsch Pharma

4 ACG Worldwide

6 Actylis

5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 BASF

1 CD Formulation

3 DFE Pharma

5 Gangwal Chemicals

1 Ideal Cures

2 Ingredion Pharma Solutions

2 Kerry

2 Keval Exports

3 Lonza Capsugel

9 Microlex e.U

3 Nitika Pharmaceutical Specialities

2 Pharmatrans-Sanaq

4 Pluviaendo

3 Prachin Chemical

1 Qualicaps

22 Roquette

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

9 Sigachi Industries

3 Silverline Chemicals

1 Ulanqab Kema New Material

3 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

48 Fillers, Diluents & Binders

18 Disintegrants & Superdisintegrants

18 Direct Compression

17 Thickeners and Stabilizers

17 Lubricants & Glidants

INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 0.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons